Pew Comments on Generic Drug Competition at FDA Public Meeting

On Sept. 18, The Pew Charitable Trusts’ drug spending research initiative submitted comments to the Food and Drug Administration in response to its public meeting, “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access.” Pew discussed ways to build on the success of the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, such as mitigating unintended barriers to competition while balancing the need to encourage innovation and protect safety and quality.